DDInter1642 DDInter1080
Sargramostim is a human recombinant granulocyte macrophage colony-stimulating factor (GM-CSF) expressed in yeast. It is a glycoprotein that is 127 residues. Substitution of Leu23 leads to a difference from native protein.
Lisocabtagene maraleucel is a chimeric antigen receptor (CAR) T-cell therapy, similar to [brexucabtagene autoleucel] and [axicabtagene ciloleucel].[A228493,L31588] Lisocabtagene maraleucel is a genetically modified autologous T-cell therapy that targets CD19, the B-lymphocyte surface antigen B4. CAR T-cell therapy has changed the treatment of B-cell lymphomas, significantly increasing survival rates over standard therapy. However, data on the efficacy of CAR T-cell therapies on less severe forms of B-cell lymphoma are lacking. Despite the adverse reactions, the majority of patients given lisocabtagene maraleucel reported an overall increase in quality of life over a 1 year period. Lisocabtagene maraleucel was granted FDA approval on 5 February 2021 and EC approval on 5 April 2022. It was later granted Health Canada approval on 6 May 2022.
Lisocabtagene maraleucel {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Filgrastim
Lisocabtagene maraleucel {u} may lead to a major life threatening interaction when taken with {v} Upadacitinib
Lisocabtagene maraleucel may cause a moderate interaction that could exacerbate diseases when taken with Filgrastim
Lisocabtagene maraleucel may lead to a major life threatening interaction when taken with Upadacitinib